Striverdi Respimat
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Striverdi (olodaterol; Boehringer Ingelheim) is a long-acting beta 2 agonist delivered via the Respimat inhaler. It is indicated for the once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Striverdi Respimat received US and EU approvals for use in COPD in July 2014 and October 2013, respectively. Datamonitor Healthcare is not aware of any specific development of olodaterol monotherapy in Japan and does not forecast the therapy for this market.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Striverdi Respimat : Chronic obstructive pulmonary disease (COPD)
LIST OF FIGURES
9 Figure 1: Striverdi Respimat for COPD – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Striverdi Respimat for COPD
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Striverdi Respimat for COPD
13 Figure 4: Striverdi Respimat sales for COPD across the US and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Striverdi Respimat drug profile
7 Table 2: Striverdi Respimat Phase III data in COPD
14 Table 3: Striverdi Respimat sales for COPD across the US and five major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Daliresp 
Sign up to the